Deltamethrin, a pyrethroid insecticide, could be a promising candidate as an anticancer agent

Area of Science:

• Oncology
• Toxicology
• Insecticide Research

Background:

• Cancer remains a leading cause of death with increasing incidence.
• Current anticancer agents have limitations in effectively treating cancer.
• Exploring novel mechanisms of existing molecules can lead to improved anticancer therapies.

Purpose of the Study:

• To investigate the potential of deltamethrin as an anticancer agent.
• To explore the apoptogenic signaling pathways induced by deltamethrin.
• To assess the therapeutic and toxic effects of deltamethrin for potential clinical application.

Main Methods:

• Review of in vitro and in vivo studies on deltamethrin's anticancer properties.
• Analysis of deltamethrin's role in inducing apoptogenic signaling pathways.
• Evaluation of deltamethrin's therapeutic and toxic effects.

Main Results:

• Deltamethrin, at low concentrations, demonstrated potential in inducing apoptogenic signaling pathways.
• These pathways are crucial for anticancer action.
• Deltamethrin exhibits potential as a novel anticancer agent.

Conclusions:

• Deltamethrin shows promise as a potential anticancer agent due to its ability to induce apoptosis.
• Further in vitro and in vivo evaluations are necessary to determine its clinical viability.
• Clinical trials require comprehensive assessment of both therapeutic benefits and toxic effects.